Jacobs Levy Equity Management
EDIT icon

Jacobs Levy Equity Management’s Editas Medicine EDIT Stock Holding History

Jacobs Levy Equity Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445K Sell
137,355
-444,954
-76% -$1.3M ﹤0.01% 839
2026
Q1 		$1.44M Sell
582,309
-244,831
-30% -$518K 0.01% 649
2025
Q4 		$1.7M Buy
827,140
+27,117
+3% +$78.3K 0.01% 611
2025
Q3 		$2.78M Buy
800,023
+707,181
+762% +$1.97M 0.01% 529
2025
Q2 		$204K Buy
+92,842
New +$152K ﹤0.01% 984
2025
Q1 		– Sell
-708,409
Closed -$900K – 1104
2024
Q4 		$900K Buy
708,409
+178,575
+34% +$455K ﹤0.01% 728
2024
Q3 		$1.81M Buy
529,834
+302,652
+133% +$1.32M 0.01% 624
2024
Q2 		$1.06M Buy
227,182
+108,042
+91% +$609K ﹤0.01% 727
2024
Q1 		$884K Sell
119,140
-165,688
-58% -$1.38M ﹤0.01% 736
2023
Q4 		$2.89M Buy
284,828
+201,732
+243% +$1.77M 0.01% 537
2023
Q3 		$648K Buy
83,096
+64,742
+353% +$555K ﹤0.01% 750
2023
Q2 		$151K Buy
+18,354
New +$160K ﹤0.01% 937
2023
Q1 		– Sell
-15,103
Closed -$134K – 991
2022
Q4 		$134K Sell
15,103
-92,035
-86% -$1.01M ﹤0.01% 921
2022
Q3 		$1.31M Buy
+107,138
New +$1.67M 0.01% 649
2022
Q2 		– Sell
-75,659
Closed -$1.44M – 1019
2022
Q1 		$1.44M Buy
+75,659
New +$1.41M 0.01% 693
2021
Q1 		– Sell
-69,345
Closed -$4.86M – 1046
2020
Q4 		$4.86M Sell
69,345
-20,675
-23% -$849K 0.04% 404
2020
Q3 		$2.53M Sell
90,020
-22,474
-20% -$732K 0.03% 474
2020
Q2 		$3.33M Buy
112,494
+45,023
+67% +$1.18M 0.04% 430
2020
Q1 		$1.34M Buy
67,471
+33,894
+101% +$855K 0.02% 560
2019
Q4 		$994K Buy
+33,577
New +$839K 0.01% 691

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jacobs Levy Equity Management's EDIT Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Editas Medicine (EDIT) stake by 76% in Q2 2026, selling an estimated $1.3M and leaving 137,355 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Jacobs Levy Equity Management first reported a position in EDIT in Q4 2019 and has held it in 20 quarters since. The position peaked at $4.86M in Q4 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Jacobs Levy Equity Management held 137,355 shares of Editas Medicine worth $445K as of Q2 2026.
  • Jacobs Levy Equity Management sold 444,954 Editas Medicine shares in Q2 2026, an estimated $1.3M.
  • Editas Medicine made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #839 holding.
  • Jacobs Levy Equity Management first reported a position in Editas Medicine in Q4 2019 and has held it in 20 quarters since.
  • Jacobs Levy Equity Management's Editas Medicine position peaked at $4.86M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.